New study tracks Ravulizumab's impact on daily life in myasthenia gravis

NCT ID NCT06909253

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 50 adults with generalized myasthenia gravis who are new to complement inhibitors and are receiving ravulizumab (Ultomiris) in Poland. Researchers will track changes in daily living activities and other symptoms over time. The goal is to see how well the drug works in routine medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ravulizumab (Ultomiris)
What this could lead to: If successful, this study could confirm that ravulizumab improves daily functioning in people with generalized myasthenia gravis who have not tried similar drugs before.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also small (50 participants) and limited to Poland, which may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS, GENERALIZED

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Bydgoszcz, Poland
Research Site
RECRUITING

Gdansk, Poland
Research Site
RECRUITING

Katowice, Poland
Research Site
RECRUITING

Krakow, Poland
Research Site
RECRUITING

Lodz, Poland
Research Site
RECRUITING

Lublin, Poland
Research Site
WITHDRAWN

Poznan, Poland
Research Site
NOT_YET_RECRUITING

Poznan, Poland
Research Site
RECRUITING

Szczecin, Poland
Research Site
NOT_YET_RECRUITING

Szczecin, Poland
Research Site
RECRUITING

Warsaw, Poland
Research Site
RECRUITING

Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.